Skip to main content

Table 3 Bivariate analyses displaying predictors of Hepatitis C therapy in HIV co-infected patients

From: Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment

Variable

HCV treatment subset

P Value

 

No (n = 94)

Yes (n = 32)

 

Gender:

   

   Female

14

7

0.56

   Male

79

25

 

Race/ethnicity:

   

   White

55

11

0.09

   Hispanic

20

9

 

   Black

17

10

 

   Unknown/other

2

2

 

Race/ethnicity, dichotomized:

   

   White

55

11

0.02

   Non-white

39

21

 

HIV risk factor:

   

   Gay/bisexual

34

13

0.96

   Heterosexual

11

3

 

   Intravenous drug use

39

13

 

   Hemophiliac

1

0

 

   Unknown/other

0

3

 

CD4 cell count (×106/l), mean (sd)

488(294)

478(272)

0.61

HIV log10 viral load, mean(sd)

2.12(0.96)

1.66(0.07)

0.01

HCV log10 RNA, mean (sd)

6.36(1.30)

6.27(1.12)

0.63

HCV genotype:

   

   Genotype 2 & 3

14

6

0.65

   Genotype 1 & 4

74

25

 

History of neuropsychiatric disease (%)

56 (60)

18 (56)

0.74

Ever use illicit substance (%)

87 (93)

28 (88)

0.38

Ongoing illicit substance use (%)

12 (13)

3 (9)

0.61

Total symptoms score, mean (sd)

73(25)

56(10)

0.002

Neuropsychiatric symptoms score, mean(sd)

28(11)

19(4)

0.00006

Somatic symptoms score, mean (sd)

19(8)

16(5)

0.0001

Sleep symptoms score, mean (sd)

4(3)

3(2)

0.04

CES-D score, mean (sd)

17(13)

8(7)

0.00003

  1. CES-D = Center for Epidemiologic Studies Depression Scale.